Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22144906 | 1.00 | CASP3 (0.47) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL17922696 | 1.00 | CASP3 (0.47) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL17922695 | 1.00 | CASP3 (0.47) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29813316 | 1.00 | CASP3 (0.47) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL17922693 | 1.00 | CASP3 (0.47) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL31488504 | 1.00 | CASP3 (0.47) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL30877991 | 1.00 | CASP3 (0.47) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL30406812 | 1.00 | CASP3 (0.47) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL31149057 | 0.95 | CASP3 (0.50) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL19134428 | 0.95 | CASP3 (0.50) | CASP3KMT2AMDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207425-A1 | AURISTATIN LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208987-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208987-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | ADCY3, ADCY8, ADCY7 | CASP3 407/4885KMT2A 1105/4885MDM4 3859/4885 |
| US-20240207425-A1 | AURISTATIN LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | AURKA, AURKC, AURKB | CASP3 933/4885KMT2A 2192/4885MDM4 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.